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Tumors rely on multiple nutrients to meet cellular bioener-
getics and macromolecular synthesis demands of rapidly divid-
ing cells. Although the role of glucose and glutamine in cancer
metabolism is well understood, the relative contribution of ace-
tate metabolism remains to be clarified. We show that gluta-
mine supplementation is not sufficient to prevent loss of cell
viability in a subset of glucose-deprived melanoma cells, but
synergizes with acetate to support cell survival. Glucose-de-
prived melanoma cells depend on both oxidative phosphoryla-
tion and acetate metabolism for cell survival. Acetate supple-
mentation significantly contributed to maintenance of ATP
levels in glucose-starved cells. Unlike acetate, short chain fatty
acids such as butyrate and propionate failed to prevent loss of
cell viability from glucose deprivation. In vivo studies revealed
that in addition to nucleo-cytoplasmic acetate assimilating
enzyme ACSS2, mitochondrial ACSS1 was critical for mela-
noma tumor growth in mice. Our data indicate that acetate
metabolism may be a potential therapeutic target for BRAF
mutant melanoma.
Malignant cells undergo metabolic reprograming to fuel
proliferation in a nutrient-limited environment. Tumor cells
metabolize glucose in the presence of oxygen, a process known
as the Warburg effect or aerobic glycolysis (1). The Warburg
effect is generally considered as a metabolic hallmark of cancer
(2), yet therapeutic targeting of underlying pathways has
remained challenging. For example, BRAF inhibitors are the
first line therapy for treatment of patients with mutant BRAF-
driven melanoma (3). However, rapid development of resis-
tance to these inhibitors involves reduction in glucose uptake
and glycolysis (4, 5). Recent studies demonstrated that tumor
cells are dependent on glutamine metabolism to support cell
proliferation (6). Glutamine metabolism enables maintenance
of tricarboxylic acid (TCA)2 cycle intermediates and plays a
critical role in suppressing oxidative stress by supplying antiox-
idants. Although glutamine can synergize with glucose metab-
olism to support tumor cell proliferation, metabolic tracing
studies in glucose-deprived cells revealed that an unknown
source of carbon cooperated with glutamine in maintaining
TCA cycle intermediates (7). Collectively, these studies suggest
that malignant cells rapidly adapt to nutrient limitation by
resetting their metabolism to maintain cell proliferation, thus
hampering effective treatments.
Similar to DNA synthesis, energy production and lipid syn-
thesis are crucial biochemical processes in rapidly dividing can-
cer cells. Acetyl-CoA, a mitochondrial metabolite responsible
for the TCA cycle and energy production is also the primary
substrate for lipid synthesis. ATP citrate lyase (ACLY) plays a
central role inmobilizing acetyl-CoA from themitochondria to
the cytoplasm. ACLY overexpression is frequently observed in
tumors and its inhibition reduces tumor growth (8). Although
BRAF inhibitor resistant melanoma shows reduced glucose
uptake (4, 5), as opposed to the Warburg effect, these tumors
gain mitochondrial functions to retain malignant growth
potential (9–12).Moreover, theWarburg effect limits the entry
of carbon into mitochondria by promoting lactate production
(13). We reasoned that in addition to glutamine metabolism
theremust be other sources of carbon that contribute to acetyl-
CoA production to support the growth of melanoma cells.
Clinical imaging studies using [11C]acetate have established
rapid uptake of acetate in several solid tumors (14–16). Impor-
tantly, tumors that showed reduced glucose uptake correlated
with enhanced acetate uptake (17). These clinical studies led to
a renewed interest in acetate metabolism. Acetyl-CoA synthe-
tases (ACSS) catalyze conversion of acetate to acetyl-CoA in an
ATP-dependent reaction. Two major ACSS enzymes account
for acetate metabolism in cells. ACSS1 (also known as Acecs2)
is localized to themitochondria, whereasACSS2 (also known as
Acecs1) functions both in the cytoplasm and the nucleus (18,
19). A recent study showed that ACSS2 is responsible for the
majority of the acetate uptake, and demonstrated a reduced
tumor burden in an ACSS2 mutant hepatocellular carcinoma
mouse model (20). ACSS2-mediated acetate metabolism con-
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tributes to lipid synthesis and aggressive growth in glioblas-
toma and breast cancer (21, 22). Although ACSS1 knockdown
cells showed reduced acetate uptake and cell growth similar
to ACSS2 knockdown (17), the role of ACSS1 is not well
understood. Here we show that glucose-starved melanoma
cells are highly dependent on acetate to sustain ATP levels,
cell viability and proliferation. Conversely, depletion of
ACSS1 or ACSS2 reduced melanoma tumor growth in mice.
Collectively, our data demonstrate acetate metabolism as a
liability in melanoma.
Experimental Procedures
Cell Culture—A375, MEL 526, and MEL697 melanoma cell
lines were maintained in RPMI 1640 medium containing 0.3
g/liter L-glutamine (HyClone), 2 g/liter D-glucose (HyClone),
and 10% FBS (Sigma) and penicillin/streptomycin (Life Tech-
nologies). Cells were routinely tested for mycoplasma contam-
ination with QuickTest Mycoplasma Detection Kit (Biotool).
Antibodies and Reagents —Antibodies to ACSS1 and ACSS2
were purchased from Proteintech (Cat. 171138-1-AP) and Cell
Signaling (Cat. 3658), respectively. Rotenone and oligomycin A
were purchased fromCaymanChemical Company, glyceryl tri-
acetate (GTA) was purchased from ACROS Organics, and all
other chemical compounds were purchased from Sigma. Rote-
none and oligomycinAwere reconstituted inDMSOand added
to the cells at respective concentrations of 1 M and 1 M.
Aqueous solutions of GTA, GTP, and GTB were added to the
cells at final concentrations of 0.25% v/v.
Starvation-coupled Viability and ATP Assays—Cells were
seeded at density of 8  103 cells per well of a 96-well plate
(Greiner) in triplicates per condition in the RPMI 1640medium
(Biological Industries) and supplemented with 10% FBS, 0.3
g/liter L-glutamine (HyClone) and 2 g/liter D-glucose (Sigma)
12–16 h prior to initiation of starvation. Medium was then
exchanged to basal RPMI 1640 medium containing defined
supplements, metabolites, and/or pharmacologically active
compounds for 30–36 h. As a source of acetate, 0.25%GTAwas
added to the defined medium. In the cases of sodium acetate
and glycerol, to obtain equivalent amounts of of GTA, 35 mM
sodium acetate (pH 7.0) and 12 mM glycerol was added to the
conditioned medium. Viability was assayed using resazurin re-
agent (Biotium) in accordance with manufacturer’s protocol.
ATP was measured after 24–30 h of incubation in defined
medium using CellTiter-Glo luminescent reagent (Promega).
Fluorescent and luminescent signals were read on Synergy H1
microplate reader (BioTek Instruments).
Cell Proliferation Assay—MEL697 cells were seeded into
24-well plates (Greiner) at density of 2  104 cells per well, in
duplicates per condition, 12–16 h prior to experimentation. To
measure cellular proliferation in defined medium, cells were
grown in plain RPMI 1640 medium in the absence of FBS and
supplemented with GTA, Gln, or both for 30 h. At this point,
every 2 h cells from duplicate wells were gently scraped into the
medium and counted using Countess Automated Cell Counter
(Invitrogen).
Crystal Violet Staining—MEL697 cells were seeded into 96
well plates at density of 8 103 cells per well in triplicates per
condition in complete RPMI 1640 medium 12–16 h prior to
experimentation. Medium was then exchanged to either the
complete medium, or the defined RPMI 1640 medium supple-
mentedwith 0, 1, 5, or 10%FBS in the absence or presence of 0.3
g/L L-glutamine, 0.25% GTA, or both for 48 h. Viability was
assessed by resazurin, subsequently cells were washed with
PBS, fixed in 4% formaldehyde for 10 min, and the adherent
cells were stained with 0.5% Crystal Violet.
shRNA-mediated Gene Silencing—TRC lentiviral shRNA
vectors were obtained from Sigma. The ACSS1 was targeted by
clone TRCN0000045380 and ACSS2 with combination of
TRCN0000045563, TRCN0000045565, TRCN0000045566,
and TRCN0000045567. The control shRNA is the pLKO.1-
TRC control (Addgene, plasmid 10879). Production of viral
particles and transduction of target cells was conducted as
described elsewhere.Gene expression changeswere assessed by
RT-qPCR as we previously reported (23), using the following
primer sequences: ACSS1 forward, GTGCAGAGTCCTTG-
GCTGGG, ACSS1 reverse, TTCTTCAGCTCCACCACGCG,
ACSS2 forward, CGAGGCCCTGCAGAAGTGTC, and ACSS2
reverse,GAGTCACCCATGCCGAGCTC.
Animal Studies—NOD/scid/IL2Rgnull (NSG) mice were
bred at IU Simon Cancer Center In-Vivo Therapeutic Core
facility. 8-week-old female animals were subcutaneously
implanted with 1 million MEL526 cells that were lentivirally
transduced to express shRNA hairpins against control, ACSS1,
or ACSS2, in 100 l serum free medium into the right hind
flank. Xenograft size was measured three times a week with a
digital caliper and the ellipsoidal tumor volumeswere recorded.
All procedures were conducted in accordance with the princi-
ples outlined in the NIH Guide for the Care and Use of Labo-
ratory Animals and were approved by the Indiana University
Institutional Animal Care and Use Committee (IACUC).
Cellular Respirometry—Oxygen consumption rate (OCR) of
cultured cells was measured with an XF24 extracellular flux
analyzer (Seahorse Bioscience). Cells were seeded at 5  104
cells per well. One day before the experiment cell culture
medium was exchanged for freshly prepared RPMI 1640
medium supplemented either with 2 g/liter D-glucose, 0.25%
GTA, or 0.3 g/liter L-glutamine, and 2% serum.After 16-h treat-
ment course, measurements were performed at 37 °C in a bath
solution of fresh RMPI medium supplemented as above. Fol-
lowing three baseline OCR measurements, wells were sequen-
tially injectedwith 1MoligomycinA, 60M2,4-dinitrophenol
(DNP), and 1M rotenone 1M antimycin A. Once injected,
each compound was present in the bath medium for the dura-
tion of the experiment. Three OCR measurements were per-
formed after each injection. To ensure that the culture main-
tained sufficient oxygenation, a 3-min mix, 2-min wait cycle
occurred prior to each 3-min measurement.
Statistical Analyses—Unless stated otherwise, data presented
are mean S.D. in triplicates per condition (n 3). Statistical
analyses were done using GraphPad Prism 5, with statistical
significance determined by Holm-Sidak method.
Results
Acetate Supplementation Sustains Mutant BRAFMelanoma
Cell Viability, and Proliferation in Glucose-deprived Cells—To
gain insight into novel glucose-independent metabolic path-
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ways that may support melanoma cell survival, we developed a
starvation assay using RPMI medium lacking glucose and glu-
tamine (defined medium), and by gradual reduction of serum
concentrations to 0%. MEL697 melanoma cells harboring the
BRAFV600Emutation are rapidly dividing cells that require con-
stant supply of carbon (glucose) and nitrogen (glutamine)
sources to support cell survival and proliferation.We exploited
these features of MEL697 cells to develop glucose and serum
starvation assay to study glucose-independent metabolic path-
ways. MEL697 were seeded in regular culture medium in a
96-well plate for 12–16 h. This regular medium was then
replaced with defined medium containing glucose plus 10%
serum or without glucose plus decreasing concentrations of
serum from10 to 0%. To thismedium, glutamine (Gln) orGTA,
or Gln plus GTA, was added as indicated (Fig. 1A). GTA, also
known as triacetin has been used as a source of acetate for
cancer cells,mice, and to treat infantswithCanavan disease (24,
25). To quantify glucose-independent acetate metabolism, we
adopted an Almar Blue-based cell viability assay. The results
indicated that in glucose-deprived cells, acetate or glutamine
alone was not sufficient to maintain cell viability, whereas the
combination of acetate and glutamine significantly restored the
viability ofmelanoma cells (Fig. 1A). Subsequent to cell viability
determinations, cells were subjected to formaldehyde fixation
and stained with crystal violet to visualize the intact cells that
adhered to the plate. Although cells exposed to 10% serumwith
glucosewere stainedwith crystal violet, therewas no staining of
cells observed in the absence of glucose. Glutamine, even in the
absence of glucose retained crystal violet staining in cells cul-
tured up to 5% serum. GTA supplementation maintained crys-
tal violet staining of cells in 10% serum even in the absence of
glucose. Remarkably, consistent with the results of cell viability
assays, cells cultured in GTA- and Gln-containing medium
were positive for crystal violet stain even in the absence of
serum and glucose (Fig. 1B). Since acetate supplementation
cooperated with glutamine in restoring viability of cells in the
absence of glucose, we asked if the combination of acetate and
glutamine could support cell proliferation. MEL697 cells were
plated in definedmediumas indicated in Fig. 1, and 30 h postin-
cubation in the definedmedium, cell number counting revealed
that the combination of acetate (GTA) and glutamine was suf-
ficient to support cell proliferation even in the absence of glu-
cose and serum (Fig. 1C). Cells incubated in the medium with-
out serum, glutamine and glucosemaintained cell growth using
the nutrients that were left on the plate from the original
medium in which cells were seeded. However, after 30 h of
incubation in medium without serum, glutamine, and glucose
led to steady decrease in cell number compared with cells incu-
bated in completemedium (p 0.001). Remarkably, even in the
absence of glucose and serum, cells incubated in glutamine plus
GTA sustained cell proliferation that was significantly higher
than that of the cell growth in complete medium (p  0.001).
Percent change in cell number was also plotted (supplemental
Fig. S1).
Glutamine but Not Acetate Supports the Viability of Mutant
NRAS andWild-type BRAF/NRASMelanomaCells Deprived of
Glucose—Although BRAF mutation is observed in 50% of mel-
anomas, nearly 20% of melanomas harbor mutations in NRAS
FIGURE1.Acetate supplementation restores cell viability andproliferation inglucose-deprivedMEL697melanomacells.A, cell viability ofMEL697 cells
grown in defined medium with added nutrients as indicated. Viability was assessed using a modified Alamar Blue reagent by fluorometry. Values represent
averages of triplicates. Statistical analysis was conducted using Bonferroni’s Multiple Comparison Test; ***, p 0.001. B, crystal violet staining of MEL697 cells
cultured in a basal RPMI medium supplemented with indicated nutrients. Glu, glucose; Gln, glutamine. C, proliferation of MEL697 cells grown in basal RPMI
medium supplemented with nutrients as indicated; ***, p 0.001.
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and also there are cases where these genes are notmutated (26).
To test whether acetate has similar effects in NRAS-mutant
and BRAF/NRAS-wild-type cells, MEL103 (NRASQ61R) and
SKMEL23 (BRAF/NRAS wild-type) melanoma cells were sub-
jected to the same starvation assay as described above. Gluta-
mine supplementation was sufficient to restore viability in both
MEL103 and SKMEL23 cells lines, and GTA supplementation
did not improve the cell viability (Fig. 2). Consistent with the
cell viability data, cell number counting in a short-term cul-
ture in the absence of glucose revealed that glutamine was
sufficient to support proliferation of MEL103 and SKMEL23
cells (supplemental Fig. S2).
Acetate Dependence in BRAF-mutant Melanoma Cells—
Having demonstrated that acetate could replace glucose as a
carbon source in mutant BRAF but not in NRAS mutant or
BRAF/NRAS-wild-type melanoma cells, we extended these
observations to commonly used melanoma cell lines. A375 and
MEL526 are BRAFmutantmelanoma cells that are widely used
to study melanoma biology (27, 28). A375 and MEL526 were
subjected to the defined medium as described above and cell
viability was assessed. The results showed that glutamine sup-
plementation was not sufficient to restore the viability but
when combined with acetate, cell viability was restored signifi-
cantly under glucose deprivation (Fig. 3A). To further substan-
tiate these results, wemeasured ATP levels by luminescence-
based assay. A375 and MEL526 cells were subjected to
starvation conditions as described above and total ATP lev-
els determined. GTA and glutamine together significantly
restored ATP levels in the absence of glucose, recapitulating
results of the cell viability data (Fig. 3B).
Melanoma Cells Metabolize Acetate, but Not Propionate or
Butyrate—Short chain fatty acid oxidation fuels energy produc-
tion in cells. Acetate, propionate, and butyrate are two, three,
and four carbon short chain fatty acids, respectively (Fig. 4A).
GTA, glyceryl tripropionate (GTP), and glyceryl tributyrate
(GTB) are metabolized by normal and tumor cells (25, 29, 30).
To test whether melanoma cells can utilize other short-chain
fatty acids, or if the proliferative effects are limited to acetate,
we performed cell viability assay for MEL526 and A375 cells in
the presence of either GTA, GTP, or GTB in combination with
glutamine. The observed effects of metabolic mediations that
could support cell viability in the absence of glucose were lim-
ited to acetate (Fig. 4B). Because GTA metabolism can yield
acetate and glycerol, to confirm the observed effects are due to
acetate but not glycerol, we conducted cell viability assay in the
presence of sodium acetate or glycerol. MEL526 and A375 cells
were subjected to conditioned medium in the presence of ace-
tate or glycerol. Similar to the effects of GTA, sodium acetate
but not glycerol restored viability of cells in the absence of
serum and glucose (supplemental Fig. S3) (p 0.001).
Glucose-independent Acetate Metabolism in Melanoma
Involves Oxidative Phosphorylation—Our previous report (23),
and studies by others (31, 32), suggest that melanoma cells
are highly dependent on glycolysis. This led us to hypothesize
that glucose-deprivation imposes oxidative phosphorylation
(OXPHOS)-dependent acetate metabolism in melanoma cells.
To test this, A375 and MEL526 cells were cultured in defined
medium containing 10% serumwith (pink bars) or without glu-
cose (gray bars) in the presence of either glutamine, GTA, or a
combination of both, and treated with OXPHOS inhibitors oli-
gomycin A or rotenone (Fig. 5A). Although neither oligomycin
A nor rotenone exposure was cytotoxic to melanoma cells in
the presence of glucose, viability of A375 andMEL526 cells was
dramatically decreased by these OXPHOS inhibitors in the
absence of glucose. To further confirm these results, A375 cells
were cultured in the defined medium with or without glucose
and in the presence or absence of glutamine plus GTA, and
oxygen consumption rate (OCR) and extracellular acidification
rate (ECAR) were measured. A dramatic increase in basal OCR
was recorded in the absence of glucose (Fig. 5B). However, a
reduced ECAR was recorded in cells cultured in glucose-de-
plete medium (Fig. 5C). These results suggest a metabolic shift
from glycolysis to OXPHOS. Although DNP induced OCR in
the presence of glucose, in the absence of glucose, GTA plus
glutamine failed to showDNP response. The following two rea-
sons may explain this failure to stimulate OCR by DNP. As
shown in Fig. 5A, OXPHOS inhibitors are cytotoxic to mela-
noma cells in the absence of glucose and therefore DNP failed
to stimulate OCR after oligomycin injection. A mechanistic
explanation to this DNP response is that acetate to acetyl-CoA
conversion requires ATP (18). Since oligomycinA inhibits ATP
production, cells are unable to metabolize acetate in glucose-
deplete medium and hence due to substrate limitations, DNP
FIGURE 2.Glutamine but not acetate reverses the effects of glucose star-
vation in a subset of melanoma. MEL103 (NRasQ61R) and SKMEL23 (BRAF/
NRas-wild-type) melanoma cells were subjected to glucose-starvation assay
in the presence of acetate or glutamine or in combination and cell viability
was assessed. ***, p 0.001.
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failed to stimulateOCR. The overall weaker response toDNP in
melanoma cells is consistent with the findings that pyruvate
transport intomitochondria is impaired in tumor cells (33–36).
These observations led us to test whether mitochondria-per-
meable methyl-pyruvate allow DNP-mediated stimulation of
OCR inmelanoma cells. Althoughmethyl-pyruvate produced a
FIGURE 3. Acetate dependence in BRAF mutant melanoma. A, cell viability of A375 and MEL526 cells grown in defined medium with added nutrients as
indicated. Viability was assessed using a modified Alamar Blue reagent by fluorometry. Values represent averages of triplicates. Statistical analysis was
conducted using Bonferroni’s Multiple Comparison Test; ***, p  0.001. B, A375 and MEL526 cells cultured in defined medium and ATP levels assessed by
luminescence-based assay; ***, p 0.001.
FIGURE4.Acetatebutnotpropionateorbutyrate supportsglucose-independent cell viability.A, structures of two, three, and four carbon sources asGTA,
GTP, and GTB, respectively. B, cell viability of A375 and MEL526 cells in basal RPMI medium supplemented either with GTA or related short-chain fatty acids.
Statistical analysis was conducted using Bonferroni’s Multiple Comparison Test; ***, p 0.001.
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robust induction of OCR by DNP in the presence of glucose,
DNP failed to stimulate OCR in glucose-deplete condition
(supplemental Fig. S4). To assess cytochrome c oxidase (COX)
activity, mitochondria isolated from glucose-replete and glucose-
deplete cells were subjected toCOXassay. A significantly elevated
COXactivitywas recorded inglucose-deplete cells comparedwith
mitochondria from glucose-replete cells (supplemental Fig. S5).
These results establish thatmitochondrial substrate limitations
FIGURE 5.Glucose-deprived cells switch to oxidative phosphorylation in acetate-mediated cell survival.A, MEL526 andA375 cells were grown in a basal
RPMImediumwith indicatednutrients, in thepresenceofATP synthase inhibitor oligomycinAor the electron transport chain complex I inhibitor rotenoneand
cell viability was assessed. B, oxygen consumption ratemeasurements of A375 andMEL526 cells in basal RPMImedium supplemented as indicated. Each data
point is an average of five replicates. C, extra cellular acidification rate measurements of A375 and MEL526 cells in basal RPMI medium supplemented as
indicated.D, crystal violet stain of A375 cells cultured in the presence or absence of glucose and/or GTA and glutamine and treatedwith either vehicle (DMSO)
or oligomycin A.
Acetate Dependency inMelanoma
21874 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 42•OCTOBER 14, 2016
stem DNP response in melanoma cells. To further substantiate
these results, A375 cells were cultured in the presence or
absence of glucose as well as glutamine plus GTA, and treated
with oligomycin. Cells were fixed and stainedwith crystal violet
to visualize intact adherent cells. Although glucose-replete cells
stained with crystal violet, no staining was observed in glucose-
starved A375 cells, suggesting that oligomycin was cytotoxic to
cells in the absence of glucose (Fig. 5C).
Acetate Metabolism Promotes Melanoma Tumor Growth in
Mice—Having demonstrated that glucose-deprived melanoma
cells switch to OXPHOS and metabolize acetate to maintain
ATP levels and cell survival, we hypothesized that acetate sup-
plementation promotes induction of ACSS1 and ACSS2 tran-
script levels. To test this, A375 cells cultured in glucose-
deprivedmedium containing GTA or glutamine, or a combina-
tion of these nutrients, and transcript levels of ACSS1, ACSS2
and the glycolytic enzyme PKM2 were quantified. Although
PKM2 transcript levels were not increased by acetate supple-
mentation, transcript levels of ACSS1 and ACSS2 were
increased by acetate supplementation, and were further
enhanced when combined with glutamine (Fig. 6A). Consistent
with the transcript levels, combined incubation of acetate plus
glutamine increased the levels of ACSS1 and ACSS2 protein
levels (Fig. 6B). These results led to the consideration that
FIGURE 6.Acetate supplementation induces ACSS1 and ACSS2 gene transcripts and depletion of these transcripts reduces the growth ofmelanoma
xenografts. A, quantitative transcript analysis of ACSS1, ACSS2, and PKM2. A375 cells were cultured in glucose-deprived medium supplemented with
glutamine, or GTA, or in combination and the levels of indicated transcripts were assessed by quantitative real-time PCR. B, cell extracts prepared from
conditions as in Fig. 6Awere blottedwith indicated antibodies.C, knockdownof ACSS1 or ACSS2 reducedmelanoma xenograft tumor volumes, as assessed by
ellipsoid tumor volumemeasurements.MEL526 cellswere transducedwith lentivirus expressing shCont, shACSS1, or shACSS2 and implanted inNSGmice. The
average S.D. (n 3) from each group at each time point is shown. **, p 0.01; ***, p 0.001. D, representative images of gross isolated tumor specimens.
E, average tumor mass is plotted. *, p 0.01 as compared with control.
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depletion of ACSS1 or ACSS2 may reduce melanoma tumor
growth in mice. To this end, MEL526 cells were transduced
with lentivirus expressing shACSS1or shACSS2 and the knock-
down efficiency was assessed by RT-qPCR (supplemental Fig.
S6). In agreement with the transcript data, depletion of
ACSS1/2 reduced the levels of ACSS1/2 proteins (supplemen-
tal Fig. S6). ACSS1 knockdown reduced 80% of its transcript
with no change in the levels of ACSS2 transcripts. ACSS2
knockdown depleted nearly 90% of its transcripts with a small
increase in the levels of ACSS1 transcript. To assess the effects
of ACSS1 and ACSS2 knockdown on melanoma tumor growth
in mice, MEL526 cells were transduced with these lentiviral
shRNAs and implanted in NSG mice subcutaneously, as we
previously reported (23). Depletion of ACSS1 or ACSS2 signif-
icantly reduced the growth of tumors as compared with the
control group (Fig. 6C). Tumors were collected from the mice
and the mass of the tumors recorded. Consistent with the
reduced tumor growth, depletion of ACSS1 orACSS2 showed a
significant reduction in tumor weight (Fig. 6, D and E). Collec-
tively, in vitro and in vivo results presented here provide strong
evidence for acetate-dependence in melanoma.
Discussion
Metabolic plasticity allows malignant cells to survive and
proliferate in a nutrient-limited tumor microenvironment.
Melanoma cells provide an excellentmodel system to study this
metabolic plasticity, as the development of resistance to BRAF
inhibitors involves a metabolic switch from glycolysis to
OXPHOS (9–12). Our present study shows that glucose-de-
prived melanoma cells heavily rely on acetate metabolism for
survival. Although recent studies have implicated nucleo-cyto-
plasmic acetate assimilating enzyme ACSS2 in tumor growth
(20–22), we now show that melanoma tumor growth in vivo is
also dependent on mitochondrial enzyme ACSS1.
Remarkably, our findings establish that acetate dependence
is specific to mutant BRAF but not mutant NRAS or wild-type
BRAF/NRAS melanoma cells. Although NRAS mutation pro-
motes glutamine metabolism and supports the growth of pan-
creatic ductal adenocarcinoma (37), uniquemetabolic adaption
mediated by mutant BRAF has remained unclear. Our results
demonstrate that melanoma cells harboring BRAF mutation
readily adapt to acetate as a carbon source in place of glucose.
Since melanoma therapy targeting mutant BRAF leads to
reduction in glycolysis and increase in mitochondrial functions
(4, 9–12), it is possible that mitochondrial acetate metabolism
may contribute to rapid development of resistance to this ther-
apy. In addition, we demonstrated that NRAS mutant and
BRAF/NARS-wild type melanoma cells primarily relay on glu-
tamine but not acetate. These observations clearly establish a
link between oncogenic mutations and specific metabolic
adaptations.
Glucose-deprived melanoma cells are dependent on acetate
to sustain ATP levels and cell proliferation in cooperation with
glutaminemetabolism, yet the sources of acetate in vivo remain
unclear. However, a broad range of acetate concentration (50–
200 M) was detected in human and murine blood (38–40).
Carbohydrate fermentation in human gut yields short chain
fatty acids including acetate, propionic, and butyric acids,
which contributes to high levels of acetate in the blood (39).
Supplementation of melanoma cells with glycerol derivative of
acetate but not propionate or butyrate was sufficient to restore
cell viability from glucose deprivation. Since GTA stimulated
induction of ACSS1 andACSS2 transcripts in glucose-deprived
cells, and GTP and GTB did not reverse the effects of glucose
deprivation, GTA-derived acetate can be attributed to the bio-
logical, biochemical and metabolic results of our studies.
Although advanced stage melanoma is highly metastatic, pri-
mary melanoma resides in the skin. The skin harbors a rich
microbiome (41), and it is an open question as to whether the
skin microbiome can be a source of acetate for a subset of mel-
anoma. While this paper was under review, a series of reports
showed that gut microbiome contributes to acetate-mediated
metabolic syndrome (42–45). The reliance on aerobic glycoly-
sis of melanoma cells increases lactate secretion, which repro-
grams the tumor microenvironment to evade the immune sys-
tem and promote tumor growth (46). Since BRAF inhibitor-
resistant melanoma showed reduced glucose uptake and
glycolysis while retaining aggressive growth characteristics
(9–12), it is tempting to speculate that these glucose-starved
tumorsmay reprogram themicroenvironment for the supply of
acetate.
Results of cell viability from OXPHOS inhibitors-treated
cells and OCR measurements from glucose-replete cells sug-
gest that melanoma cells derive energy primarily from glycoly-
sis. A metabolic adaptability was evident from the fact that
OXPHOS inhibitors were not cytotoxic to melanoma cells in
the presence of glucose. Conversely, glucose-starved cells
showed a robust increase in basal OCR while maintaining low
ECAR and were sensitive to OXPHOS inhibitors. The observa-
tion that in glucose-deplete cells, GTA plus glutamine failed to
stimulate OCR by DNP is worthy of discussion. Importantly,
acetate to acetyl-CoA conversion is an ATP-dependent pro-
cess, which can be inhibited by oligomycin. However, oligomy-
cin-resistant ATP from glycolysis can support mitochondrial
acetatemetabolism,which can supplyNADH to electron trans-
port chain and can respond to DNP. Because lack of glucose
abrogates this response, it is reasonable to propose that mito-
chondrial acetate metabolism contributes to DNP response in
the presence of glucose. Surprisingly, exposure to 0.55mMDNP
was not cytotoxic to melanoma cells and the DNP treatment
caused an increase in ATP levels suggesting a metabolic adap-
tation to glycolysis (9). Several studies have shown that mela-
noma cells poorly respond to protonophore FCCP and are
highly resistant to cytotoxic effects of OXPHOS inhibitors (47,
48). These observations are consistentwith the findings that the
development of resistance to BRAF inhibition was associated
with gain of mitochondrial functions (9–12). Our results sup-
port amodel inwhichmitochondrial acetatemetabolism is crit-
ical to meet the cellular bioenergetics demands of melanoma
cells. It is highly relevant to note that ACSS1 knock-out mice
showed 50% reduction of ATP levels in skeletal muscle, and
thesemice were resistant to weight gain on a low carbohydrate,
high-fat diet (49). Interestingly, genome analysis of thorough-
bred horses revealed a positive selection for ACSS1 locus (50),
and a polymorphism in ACSS1 was associated with elite race-
course performance of horses (51). These observations in the
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context of our data may explain why melanoma is more com-
monly seen in horses than any other domesticated animals (52,
53). However, we show that depletion of ACSS1 or ACSS2
reduced the growth ofmelanoma xenografts. Although glucose
starvation significantly decreases melanoma cell viability sug-
gesting glucose as a primary metabolic choice, depletion of
ACSS1 or ACSS2 caused a significant reduction in tumor
growth in vivo. Based on these observations, it is reasonable to
propose acetate metabolism as an Achilles’ heel in mutant
BRAF-driven melanoma. Since acetate to acetyl-CoA conver-
sion is also an ATP-dependent reaction, we believe that the
energy required for cytosolic acetate assimilation (ACSS2) is
derived from mitochondrial acetate metabolism (ACSS1). In
agreement with this notion, a recent study analyzing patient
samples revealed that high levels of ACSS1 was associated with
hepatocellular carcinoma tumor growth and malignancy (54).
Collectively, these observations suggest that ACSS1 contrib-
utes to aggressive tumor growth.
Remarkably, glucose concentration is 3–10-fold lower in
cancer cells than normal cells (55–57). Consistent with our
observation that glucose starved melanoma cells readily adapt
to acetate metabolism, lung cancer patients infused with
labeled glucose revealed contributions of non-glucose nutrients
to overall tumor metabolism (58). These observations suggest
that tumor cells must rely on other sources of carbon to fill the
carbon void created by glucose deficit.We propose that acetate
metabolism in melanoma presents a potential targetable vul-
nerability. Importantly, ACSS1 and ACSS2 mutant mice
develop normallywithout any overt phenotypes suggesting that
ACSS1- and ACSS2-mediated acetate metabolism is dispens-
able for normal cell functions in mice (20, 49). Because resis-
tance to BRAF inhibitor is associated with gain of mitochon-
drial functions (9–12), and that tumor cells devoid of
mitochondrial DNA show delayed tumor growth (59), it is pos-
sible that concurrent targeting of ACSS1 and mutant BRAF
may significantly improve clinical outcomes of treatment for
patients with melanoma.
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